Ascendis Pharma A/S Purchase Of Availableforsale Financial Assets
Ascendis Pharma A/S (ASND) reported Purchase Of Availableforsale Financial Assets of EUR 0 for the 12-month period ending 2023-12-31, per its 20-F filed 2024-02-07.
Discontinued › Notes › Investments
ifrs-full:PurchaseOfAvailableforsaleFinancialAssets · last filed 2024-02-07
- Ascendis Pharma A/S purchase of availableforsale financial assets for the quarter ending 2023-12-31 was 0.00 EUR, a 100.00% decline year-over-year.
- Ascendis Pharma A/S purchase of availableforsale financial assets for the quarter ending 2023-09-30 was 0.00 EUR, a 100.00% decline year-over-year.
- Ascendis Pharma A/S purchase of availableforsale financial assets for the quarter ending 2023-06-30 was 0.00 EUR, a 100.00% decline year-over-year.
- Ascendis Pharma A/S purchase of availableforsale financial assets for the quarter ending 2023-03-31 was 0.00 EUR, a 100.00% decline year-over-year.
| Period end | Purchase Of Availableforsale Financial Assets 3 month | Purchase Of Availableforsale Financial Assets 6 month | Purchase Of Availableforsale Financial Assets 9 month | Purchase Of Availableforsale Financial Assets 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00 EUR derived: 20-F 12 month − 6-K 9 month · filed 2024-02-07 | 0.00 EUR derived: sum of 2 quarters · filed 2024-02-07 | 0.00 EUR derived: sum of 3 quarters · filed 2024-02-07 | 0.00 EUR 20-F · filed 2024-02-07 |
| 2023-09-30 | 0.00 EUR derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | 0.00 EUR derived: sum of 2 quarters · filed 2023-11-07 | 0.00 EUR 6-K · filed 2023-11-07 | 53.00M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2023-06-30 | 0.00 EUR derived: 6-K 6 month − 6-K 3 month · filed 2023-09-05 | 0.00 EUR 6-K · filed 2023-09-05 | 53.00M EUR derived: sum of 3 quarters · filed 2024-02-07 | 124.14M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2023-03-31 | 0.00 EUR 6-K · filed 2023-04-27 | 53.00M EUR derived: sum of 2 quarters · filed 2024-02-07 | 124.14M EUR derived: sum of 3 quarters · filed 2024-02-07 | 187.53M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-12-31 | 53.00M EUR derived: 20-F 12 month − 6-K 9 month · filed 2024-02-07 | 124.14M EUR derived: sum of 2 quarters · filed 2024-02-07 | 187.53M EUR derived: sum of 3 quarters · filed 2024-02-07 | 213.84M EUR 20-F · filed 2024-02-07 |
| 2022-09-30 | 71.14M EUR derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | 134.53M EUR derived: sum of 2 quarters · filed 2023-11-07 | 160.84M EUR 6-K · filed 2023-11-07 | 299.33M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-06-30 | 63.39M EUR derived: 6-K 6 month − 6-K 3 month · filed 2023-09-05 | 89.70M EUR 6-K · filed 2023-09-05 | 228.19M EUR derived: sum of 3 quarters · filed 2024-02-07 | 239.38M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-03-31 | 26.31M EUR 6-K · filed 2023-04-27 | 164.81M EUR derived: sum of 2 quarters · filed 2024-02-07 | 175.99M EUR derived: sum of 3 quarters · filed 2024-02-07 | 212.91M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2021-12-31 | 138.49M EUR derived: 20-F 12 month − 6-K 9 month · filed 2024-02-07 | 149.68M EUR derived: sum of 2 quarters · filed 2024-02-07 | 186.59M EUR derived: sum of 3 quarters · filed 2024-02-07 | 226.04M EUR 20-F · filed 2024-02-07 |
| 2021-09-30 | 11.19M EUR derived: 6-K 9 month − 6-K 6 month · filed 2022-11-02 | 48.10M EUR derived: sum of 2 quarters · filed 2022-11-02 | 87.54M EUR 6-K · filed 2022-11-02 | 284.90M EUR derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-06-30 | 36.91M EUR derived: 6-K 6 month − 6-K 3 month · filed 2022-08-10 | 76.36M EUR 6-K · filed 2022-08-10 | 273.72M EUR derived: sum of 3 quarters · filed 2023-02-16 | 380.66M EUR derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-03-31 | 39.44M EUR 6-K · filed 2022-05-11 | 236.81M EUR derived: sum of 2 quarters · filed 2023-02-16 | 343.75M EUR derived: sum of 3 quarters · filed 2023-02-16 | |
| 2020-12-31 | 197.36M EUR derived: 20-F 12 month − 6-K 9 month · filed 2023-02-16 | 304.31M EUR derived: sum of 2 quarters · filed 2023-02-16 | 537.75M EUR 20-F · filed 2023-02-16 | |
| 2020-09-30 | 106.94M EUR derived: 6-K 9 month − 6-K 6 month · filed 2021-11-10 | 340.39M EUR 6-K · filed 2021-11-10 | ||
| 2020-06-30 | 233.45M EUR 6-K · filed 2021-08-27 |